Tag:
solanezumab
Latest Headlines
Latest Headlines
TheStreet: A roundup of the top drug studies left in 2012
Any forward-looking student of the biotech industry will have to check out Adam Feuerstein's review in TheStreet of 22 Phase II and III clinical trials--21 drugs and one diagnostic test--which are expected to read out by the end of this year.
Genentech drug picked for pioneering $100M Alzheimer's trial
Investigators will test the drug in a region of Colombia where a particular genetic mutation is known to trigger the early onset of Alzheimer's.
Big Pharma's high-risk pursuit of CNS gold faces major market doubts
Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.
Lilly CEO avoids Pfizer-like cuts, focuses on pipeline
John Lechleiter has held firm to his position that cutting expenses alone isn't a solution to the challenges at his company; he thinks that the way forward resides in the pipeline.
Lilly gains FDA approval for its controversial brain plaque test
Late on Friday, Eli Lilly put out the word that the FDA had approved its brain dye--Amyvid--for use in ruling out Alzheimer's.
Pfizer R&D chief talks up chances for late-stage Alzheimer's drug
Chasing one of the holy grails in the drug business, Pfizer ( $PFE ) research boss Mikael Dolsten made a case for investors and industry watchers yesterday for why his company's and Johnson &
Is Lilly betting the farm on its high-stakes Alzheimer's gamble?
Now that the patent cliff has arrived right on time for Eli Lilly ( $LLY ), the big question this year is whether or not its massive gamble on the Alzheimer's drug solanezumab will pay off. That's
Lilly's losses put pressure on key Alzheimer's program
Eli Lilly ( $LLY ) saw its fourth-quarter profit slide 27% after the loss of its patent on Zyprexa last year hit sales of the schizophrenia drug harder than expected, Bloomberg reported. And the fresh
Bleak forecast puts Eli Lilly's ambitious R&D game plan to the test
Eli Lilly ( $LLY ) stepped right up to the edge of the patent cliff this morning, looked down and predicted a $3 billion drop in Zyprexa sales as cheaper generics muscle into the market. The bleak
Surge in Lilly shares highlights perils, potential of Alzheimer's drugs
Yesterday Tim Anderson, a top analyst at Bernstein, helped underscore why a few Big Pharma companies and legions of investors are so enamored with the potential mega-market for new Alzheimer's drugs.
